In vitro treatment of FSHD cells with 3 different concentrations of siRNA (0.5, 1, and 2 μM) produced dose-dependent reductions in 3 human DUX4 target transcripts. The gene discussed is DUX4; the disease is facioscapulohumeral muscular dystrophy.